AASLD 2024

Note: The following publications may contain information that is not consistent with the approved prescribing information for resmetirom. These publications do not constitute a recommendation for use outside of country-specific labeling.

All Categories
Download all
  • AASLD 2024 - Clinical
TitleDescriptionDownload
Resmetirom Therapy of MASH-Associated Child Pugh A Cirrhosis Reduces Estimated Risk for Clinical Outcome Based on HepQuant RISK ACE Model

Poster Presentation

 DownloadPreview
Validating pre-identified morphological baseline features for predicting fibrosis progression in MAESTRO-NASH

Poster Presentation

 DownloadPreview
Resmetirom effects on NASH with liver fibrosis in patients with NASH genetic risk alleles

Oral Presentation

 DownloadPreview
Effect of Resmetirom or Placebo in NASH Fibrosis Patients With <5% or ≥5% Weight Loss and-or on Baseline GLP-1 Therapy in the MAESTRO-NASH 52-Week Serial Liver Biopsy Study

Oral Presentation 

 DownloadPreview
Assessment of resmetirom efficacy (80 mg vs 100 mg) stratified by baseline body mass index and weight in patients from the MAESTRO-NASH trialPoster Presentation DownloadPreview
Impact of resmetirom on statin pharmacokinetics safety in Phase 1 and 3 studies; safety and efficacy of resmetirom in patients on statins in MAESTRO-NASHPoster Presentation DownloadPreview
Liver enzymes reductions from baseline over time in resmetirom treated patients in a Phase 3 study, MAESTRO-NASHPoster Presentation DownloadPreview
Baseline characteristics in well-compensated NASH cirrhosis patients diagnosed with or without a liver biopsy in MAESTRO-NASH-OUTCOMES, a clinical outcome Phase 3 study assessing the effect of resmetirom in well-compensated NASH cirrhosisPoster Presentation DownloadPreview
Use of non-invasive tests to diagnose and follow NASH with liver fibrosis patients treated with resmetiromPoster Presentation DownloadPreview
Download all
  • AASLD 2024 - HEOR
TitleDescriptionDownload
Current multi-dimensional view of non-alcoholic steatohepatitis (NASH) - metabolic dysfunction-associated steatohepatitis (MASH) global epidemiological ratesPoster Presentation DownloadPreview
Risk of incident extrahepatic cancers among Medicare patients with non-alcoholic steatohepatitis (NASH)Poster Presentation DownloadPreview

Resmetirom is currently only approved in the United States.